#AS­CO21: J&J busts out a small up­date for its an­ti­body-TKI com­bo in lung can­cer — whet­ting ap­petites as FDA thinks it over

In a red-hot EGFR-mu­tat­ed non-small cell lung can­cer mar­ket, John­son & John­son thinks it could have a leader in its bis­pe­cif­ic an­ti­body ami­van­tam­ab. But as com­peti­tors crowd in, J&J is look­ing to back up its case for ap­proval, and it’s rolling out just a taste of that da­ta to back its case in rare mu­ta­tions.

A com­bi­na­tion of J&J’s EGFR/MET bis­pe­cif­ic an­ti­body ami­van­tam­ab and small-mol­e­cule TKI drug laz­er­tinib post­ed a me­di­an du­ra­tion of re­sponse of 9.6 months in pa­tients with NSCLC with ex­on 19 dele­tion or L858R mu­ta­tion that hadn’t pre­vi­ous­ly un­der­gone chemo but pre­vi­ous­ly failed on As­traZeneca’s Tagris­so, ac­cord­ing to co­hort da­ta from the Phase I/II CHRYSALIS study set to be pre­sent­ed at AS­CO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.